Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS
Contenu archivé le 2024-06-20

Molecular mechanisms underlying chemotherapy resistance, therapeutic escape, efficacy and toxicity

Objectif

The overall aim of the proposed project is to improve the outcome of cancer chemotherapy by developing novel tools to predict tumour response to treatment as well as individual toxicity to chemotherapy. The projectwill seek to identify and validate mechanisms of intrinsic and acquired chemotherapy resistance, as well as predictors of efficacy and of individual toxicity. This is achieved by integrating the work of groups conducting large clinical trials with preclinical research groups, as well as with state of the art-platforms for genomic and proteomic analyses and bioinformatics.
The participants have chosen to focus on melanoma and lung cancer as model tumours of separate histogenetic types exhibiting intrinsic resistance and/or a high degree of acquired resistance to chemotherapy. Candidate mechanisms of drug resistance and therapeutic efficacy will be identified using genomic and proteomic analyses of sequential tumour samples and paired sera obtained before and after chemotherapy as well as experimental systems, including in vitro studies of tumour cell lines, transplanted human tumours and novel animal tumour models,. These putative mechanisms will then be validated in further analyses of larger sets of tumour biopsies from patients. Functional studies of novel mechanisms and pathways will be also performed using in-vitro systems and animal models.
The result of these activities will thus be a set of clinically and functionally validated mechanisms of chemotherapy resistance and therapeutic efficacy. Likewise, large scale genomic analyses of patients receiving chemotherapy as part of clinical trials will be performed in order to validate novel markers of individual toxicity following chemotherapy.The novel knowledge obtained through the project will lead to new tools for prediction of treatment outcome as well as toxicity of chemotherapy. This knowledge may also be used to identify and prepare for preclinical development of potential novel modulator.

Champ scientifique (EuroSciVoc)

Programme(s)

Thème(s)

Appel à propositions

FP6-2005-LIFESCIHEALTH-6
Voir d’autres projets de cet appel

Régime de financement

IP - Integrated Project

Coordinateur

KAROLINSKA INSTITUTET
Contribution de l’UE
Aucune donnée
Adresse
Nobels väg 5
STOCKHOLM
Suède
Coût total
Aucune donnée

Participants (18)